| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.ATHEROSCLEROSIS.2005.10.017 |
| P698 | PubMed publication ID | 16307748 |
| P50 | author | Ulf de Faire | Q29840595 |
| Anastasia Georgiades | Q105534084 | ||
| P2093 | author name string | Johan Frostegård | |
| Jun Su | |||
| Thomas Thulin | |||
| Ruihua Wu | |||
| P433 | issue | 1 | |
| P921 | main subject | antibody | Q79460 |
| patient | Q181600 | ||
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 160-166 | |
| P577 | publication date | 2005-11-22 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension | |
| P478 | volume | 188 |
| Q90307058 | Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes |
| Q47661912 | Antibodies against Phosphorylcholine among New Guineans Compared to Swedes: An Aspect of the Hygiene/Missing Old Friends Hypothesis |
| Q34634016 | Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development |
| Q46014277 | ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. |
| Q37021490 | Atherogenesis and the humoral immune response to modified lipoproteins |
| Q35752098 | Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea |
| Q37167998 | Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies |
| Q37824302 | Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases |
| Q51597663 | Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: case-control study. |
| Q47995027 | Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial |
| Q35557796 | Cardiovascular co-morbidity in patients with rheumatic diseases. |
| Q34484101 | Characterization of Gene Use and Efficacy of Mouse Monoclonal Antibodies toStreptococcus pneumoniaeSerotype 8 |
| Q35175305 | Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-year-old women |
| Q33598770 | Clinical significance of the humoral immune response to modified LDL. |
| Q52742149 | Cross-reactive antigens for natural IgE antibodies: allergens with the potential to transform a dormant to an active allergic response? |
| Q35596537 | Dendritic cells, antibodies reactive with oxLDL, and inflammation. |
| Q37980498 | Future potential biomarkers for postinterventional restenosis and accelerated atherosclerosis. |
| Q34185602 | Gluten-free diet in nonceliac disease |
| Q36757006 | Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. |
| Q28078211 | Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair |
| Q33930928 | High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes |
| Q37556461 | Human IgM Antibodies to Malondialdehyde Conjugated With Albumin Are Negatively Associated With Cardiovascular Disease Among 60-Year-Olds |
| Q56891373 | Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts |
| Q97070205 | IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases |
| Q41844631 | IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL |
| Q34275789 | IgM-antibodies against phosphorylcholine in mothers and normal or low birth weight term newborn infants |
| Q37261617 | Immune mechanisms in atherosclerosis, especially in diabetes type 2 |
| Q28688590 | Immunity, atherosclerosis and cardiovascular disease |
| Q46380048 | Immunoassay of modified forms of human low density lipoprotein in isolated circulating immune complexes |
| Q37385727 | Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice |
| Q34613997 | Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus |
| Q37578120 | Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside |
| Q39933128 | Intravenous immunoglobulins. Current understanding and future directions. |
| Q49164628 | Linking autoimmunity to the origin of the adaptive immune system |
| Q33793453 | Low level of physical activity in women with rheumatoid arthritis is associated with cardiovascular risk factors but not with body fat mass--a cross sectional study |
| Q34538210 | Low levels of IgM antibodies to oxidized cardiolipin increase and high levels decrease risk of cardiovascular disease among 60-year olds: a prospective study |
| Q30547812 | Low levels of a natural IgM antibody are associated with vein graft stenosis and failure |
| Q45354449 | Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease |
| Q42756567 | Malondialdehyde-Modified LDL IgG Antibody Levels and Indices of Cardiac Function in Valvular Heart and Coronary Artery Disease Patients |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q26752508 | Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged |
| Q27021242 | Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease |
| Q35649417 | Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics |
| Q64135771 | Nontypeable Haemophilus influenzae Invasive Blood Isolates Are Mainly Phosphorylcholine Negative and Show Decreased Complement-Mediated Killing That Is Associated with Lower Binding of IgM and CRP in Comparison to Colonizing Isolates from the Orophar |
| Q33879138 | Oxidized LDL: diversity, patterns of recognition, and pathophysiology |
| Q43089504 | Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice |
| Q43523503 | Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetes |
| Q38291820 | Prediction and management of cardiovascular outcomes in systemic lupus erythematosus |
| Q39014435 | Profile of Autoantibodies Against Phosphorylcholine and Cross-reactivity to Oxidation-Specific Neoantigens in Selective IgA Deficiency With or Without Autoimmune Diseases |
| Q57892534 | Prooxidant-Antioxidant Balance and Antioxidized LDL Antibody Level Values and Cardiac Function in Patients with Coronary Artery Disease |
| Q38774904 | Readapting the adaptive immune response - therapeutic strategies for atherosclerosis |
| Q88929970 | Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids |
| Q37434626 | Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study |
| Q37206912 | Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study |
| Q37682418 | Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody |
| Q28553042 | Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect |
| Q86635254 | Splenic extrafollicular reactions and BM plasma cells sustain IgM response associated with hypercholesterolemia |
| Q92432673 | Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice |
| Q37167995 | Systemic lupus erythematosus and cardiovascular disease. |
| Q55318081 | The Contribution of Autoantibodies to Inflammatory Cardiovascular Pathology. |
| Q38491162 | The human counterpart of mouse B-1 cells |
| Q35164643 | The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model |
| Q37731718 | The role of immune complexes in atherogenesis. |
| Q37530710 | Vaccination for atherosclerosis |
| Q43251127 | Vaccination, atherosclerosis and systemic lupus erythematosus |
Search more.